Lower Infections with Elranatamab in Multiple Myeloma in Real-World Settings | EHA 2026

Lower Infections with Elranatamab in Multiple Myeloma in Real-World Settings | EHA 2026
Can Blood Draws Replace Bone Marrow Biopsies? The Promise of Circulating Tumor Cells in Myeloma
Anselamimab shows improved survival in kappa light-chain amyloidosis - CARES study | EHA 2026
MajesTEC-3: Teclistamab + Dara in Cytogenetic & Functional High Risk Relapsed Myeloma | EHA 2026
Multiple Studies Showing Promising Results with Bispecific Antibodies | EHA 2026
Shared decision making in Newly Diagnosed Multiple Myeloma | EHA 2026
Can patients drop out of a trial if they want to? When will I be removed from a trial?
ISABELA: Isatuximab + Belantamab Mafadotin + Pom + Dex in Relapsed/ Refractory Myeloma | EHA26
Are there different ways to do MRD? Would MRD testing be multiple tests as a surrogate end point?